International Stem Cell's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.02.
During the past 3 years, the average EBIT per Share Growth Rate was 39.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 44.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 40.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for International Stem Cell's EBIT per Share or its related term are showing as below:
ISCO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30 Med: 29.1 Max: 68.9
Current: 39.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of International Stem Cell was 68.90% per year. The lowest was -30.00% per year. And the median was 29.10% per year.
ISCO's 3-Year EBIT Growth Rate is ranked better than 87.97% of 1305
companies
in the Biotechnology industry
Industry Median: 3.4
vs ISCO: 39.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (OTCPK:ISCO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
International Stem Cell EBIT per Share Related Terms
Thank you for viewing the detailed overview of International Stem Cell's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
International Stem Cell (International Stem Cell) Business Description
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ISCO has been successfully added to your 